Dimethylformamide → HCID 66851307, compound
Reaction equation
[Cl:1][C:2]1[CH:3]=[C:4]([C:8]2[C:12]([NH:13][C:14]([C:16]3[CH:24]=C4N=CC=CN4N=3)=[O:15])=[CH:11][NH:10][N:9]=2)[CH:5]=[CH:6][CH:7]=1.[CH3:25][C:26]1([O:29][CH2:28]1)[CH3:27].C(=O)([O-])[O-].[Cs+].[Cs+].C[N:37]([CH3:40])[CH:38]=O>>[Cl:1][C:2]1[CH:3]=[C:4]([C:8]2[C:12]([NH:13][C:14]([C:16]3[CH:24]=[N:10][N:9]4[CH:8]=[CH:4][CH:40]=[N:37][C:38]=34)=[O:15])=[CH:11][N:10]([CH2:25][C:26]([OH:29])([CH3:28])[CH3:27])[N:9]=2)[CH:5]=[CH:6][CH:7]=1Participants
Conditions
- Temperature
- 50 °C
Procedure
N-(3-(3-chlorophenyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-carboxamide (58.9 mg, 0.174 mmol, 1 eq) was dissolved in 5 mL N,N-dimethylformamide. To this solution was added isobutylene oxide (0.5 mL, 6 mmol, 30 eq) and cesium carbonate (56.4 mg, 0.173 mmol, 1.0 eq). The reaction mixture was stirred at 50° C. for 7.5 hours. The reaction mixture was partitioned between ethyl acetate and water, and the organic portion washed with brine, dried over magnesium sulfate and concentrated. The crude product was purified by reverse phase HPLC and lyophilized to give 33.1 mg (46%) of N-(3-(3-chlorophenyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide. LCMS (ESI) m+H=411.1; 1H NMR (400 MHz, DMSO-d6) δ: 10.02 (s, 1H), 9.36 (d, 1H), 8.83 (d, 1H), 8.69 (s, 1H), 8.35 (s, 1H), 7.84 (s, 1H), 7.76 (d, 1H), 7.58 (t, 1H), 7.49 (d, 1H), 7.33 (d of d, 1H), 4.73 (s, 1H), 4.09 (s, 2H), 1.13 (s, 6H).
Workup
- customThe reaction mixture was partitioned between ethyl acetate and water
- washthe organic portion washed with brine
- dry with materialdried over magnesium sulfate
- concentrationconcentrated
- customThe crude product was purified by reverse phase HPLC
Sources & evidence
- ORD record
- ord-63d66295ee3f417bbcffefd9d5de30ce
- Source dataset
- uspto-grants-2015_04
- Patent number
- US08999998B2
Reaction notes
Loading…